A forward-thinking team of researchers at The University of Illinois, Urbana-Champaign have discovered an unconventional method to treat a prevalent disorder called endometriosis. The team utilizes two new drug compounds which overturn the assumptions of traditional treatment and drastically improve results.
Endometriosis is a disorder driven by estrogen and inflammation that afflicts around 15 percent of reproductive-age women in the US. Its effects include scarring of the ovaries and fallopian tubes, chronic pain, and even infertility. Existing pharmaceutical treatments fall short in the sense that they do not reliably reduce the pain and inflammation of the disorder.
“Current treatments also have side effects on other tissues through which estrogens work, and so they can’t be taken forever,” said Urbana-Champaign chemistry professor John Katzenellenbogen in a recent UIUC press release. Knowing there must be some better solution, Katzenellenbogen and the team looked at the problem a new way: instead of trying to improve the current treatment, examine whether the current treatment is even targeting the right things.
(The UIUC research team, courtesy UIUC)
“The usual treatments for endometriosis are aimed at suppressing estrogen production because it’s an estrogen-driven disease,” said molecular and integrative physiology professor Benita Katzenellenbogen (image left, courtesy UIUC). “We thought that a better approach might be to interfere with both of the main aspects of endometriosis: the growth-promoting actions and also the inflammatory aspects – both of which involve the estrogen receptor.”
With this goal in mind, the team discovered two new compounds named chloroindazole (CLI) and oxabicycloheptene sulfonate (OBHS) that reduce inflammation and decrease the size of growths caused by endometriosis. In mouse models, the compounds also didn’t cause any adverse side effects; in fact, the subjects even gave birth to perfectly healthy baby mice.
In addition, the team found that adding either compound to conventional treatment did a better job of suppressing the endometriosis than the treatment alone. The team hopes that the compounds can be used to treat several disorders linked to estrogen and inflammation such as multiple sclerosis, inflammatory breast cancer, liver fibrosis, and even cardiovascular and metabolic problems associated with obesity.
Funding for this study came from The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health. More funding information related to the University of Illinois, Urbana-Champaign and the research it conducts can be found using the link below:
If you are a UIUC researcher or laboratory supplier, and would like to boost awareness of your products and increase scientific sales, plan to attend Biotechnology Calendar, Inc.'s annual Urbana-Champaign BioResearch Product Faire™, coming up on October 7, 2015 on the University of Illinois campus. While you’re in the area, consider attending BCI’s Chicago BioResearch Product Faire™ two days later on October 9, 2015. Biotechnology Calendar, Inc. has been bringing life science research trade shows to top research campuses for 20 years now. If you’d like to attend a show closer to home, please see our 2015 schedule of events.
